Brown Brothers Harriman & Co’s Aurinia Pharmaceuticals AUPH Stock Holding History

Brown Brothers Harriman & Co’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,500	Closed	-$144	–	1156
2021 Q3	$144	Hold	6,500	–	–	﹤0.01%	511
2021 Q2	$84	Hold	6,500	–	–	﹤0.01%	581
2021 Q1	$84	Hold	6,500	–	–	﹤0.01%	554
2020 Q4	$90K	Hold	6,500	–	–	﹤0.01%	573
2020 Q3	$96K	Hold	6,500	–	–	﹤0.01%	496
2020 Q2	$106K	Hold	6,500	–	–	﹤0.01%	478
2020 Q1	$94K	Hold	6,500	–	–	﹤0.01%	447
2019 Q4	$132K	Hold	6,500	–	–	﹤0.01%	531
2019 Q3	$35K	Hold	6,500	–	–	﹤0.01%	703
2019 Q2	$43K	Hold	6,500	–	–	﹤0.01%	607
2019 Q1	$42K	Hold	6,500	–	–	﹤0.01%	607
2018 Q4	$44K	Hold	6,500	–	–	﹤0.01%	527
2018 Q3	$43K	Hold	6,500	–	–	﹤0.01%	534
2018 Q2	$37K	Hold	6,500	–	–	﹤0.01%	529
2018 Q1	$34K	Hold	6,500	–	–	﹤0.01%	514
2017 Q4	$29K	Hold	6,500	–	–	﹤0.01%	584
2017 Q3	$41K	Hold	6,500	–	–	﹤0.01%	499
2017 Q2	$40K	Hold	6,500	–	–	﹤0.01%	506
2017 Q1	$48K	Buy	+6,500	New	+$30K	﹤0.01%	494

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

MAM

Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Brown Brothers Harriman & Co's AUPH Position: Q4 2021 in Review

Brown Brothers Harriman & Co sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2021, closing a stake of 6,500 shares — an estimated $144 sold.

Brown Brothers Harriman & Co first reported a position in AUPH in Q1 2017 and held it in 19 quarters. The position peaked at $132K in Q4 2019. 190 funds tracked by Wall St. Rank hold AUPH as of Q4 2021.

Brown Brothers Harriman & Co reported no remaining Aurinia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Brown Brothers Harriman & Co sold 6,500 Aurinia Pharmaceuticals shares in Q4 2021, an estimated $144.
Brown Brothers Harriman & Co first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 19 quarters.
Brown Brothers Harriman & Co's Aurinia Pharmaceuticals position peaked at $132K in Q4 2019.
190 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2021.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.